Group 1 - The company expects a net loss for the fiscal year 2025, with the performance forecast period from January 1, 2025, to December 31, 2025 [1] - The financial data related to the performance forecast has not been audited by the accounting firm, but preliminary communication indicates no significant discrepancies [1][2] Group 2 - The primary reason for the expected loss is high fixed costs, particularly depreciation expenses on fixed assets [2] - The company anticipates a reduction in losses compared to the previous year, mainly due to a decrease in the provision for impairment of fixed assets [2]

Core Viewpoint - ST Tian Sheng (002872.SZ) is forecasting a net loss for the fiscal year 2025, with expected losses ranging from 52 million to 76 million yuan, compared to a loss of 87.4 million yuan in the same period last year [1] Financial Performance - The projected net loss attributable to shareholders is between 52 million and 76 million yuan for 2025, which is an improvement from the previous year's loss of 87.4 million yuan [1] - The net profit after deducting non-recurring gains and losses is expected to be a loss of 60 million to 88 million yuan, compared to a loss of 110 million yuan in the previous year [1] Reasons for Loss - The primary reason for the company's losses is attributed to high fixed costs, particularly depreciation expenses related to fixed assets [1] - The anticipated reduction in losses for 2025 is mainly due to a decrease in the provision for fixed asset impairment compared to the previous year [1]

Financial Performance Expectations - The company expects a net profit of -76 million yuan for the year 2025, compared to -52 million yuan in the same period last year [3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be -88 million yuan, down from -60 million yuan year-on-year [4]. - Basic earnings per share are expected to be -0.2390 yuan, compared to -0.1635 yuan in the previous year [4]. Reasons for Expected Loss - The primary reason for the expected loss is high fixed costs, particularly depreciation of fixed assets [6]. - The company anticipates a reduction in losses for 2025 compared to the previous year due to a decrease in the provision for fixed asset impairment [6]. Financial Data and Audit Status - The financial data in the earnings forecast has not been audited by the accounting firm, and the final figures will be confirmed in the 2025 annual report [7]. - The company has communicated with the accounting firm regarding the earnings forecast, and there are no significant discrepancies [5]. Investor Caution - Investors are advised to exercise caution and consider investment risks based on the preliminary nature of the financial data [8].

Summary of Key Points Core Viewpoint - Tian Sheng Pharmaceutical Group Co., Ltd. has provided guarantees for its subsidiary and accepted guarantees from related parties, which involves a credit application of 27 million RMB from Hubei Tian Sheng Pharmaceutical Co., Ltd. to Chongqing Rural Commercial Bank [1][2]. Group 1: Guarantee Overview - The company approved a credit guarantee for its wholly-owned subsidiary, Hubei Tian Sheng, amounting to 27 million RMB, with the guarantee provided by the company and related party Liu Shuang [1][2]. - The guarantee is within the previously approved limit and does not require further board or shareholder approval [2]. Group 2: Details of the Guarantee - The maximum debt amount guaranteed is 27 million RMB, covering principal, interest, penalties, and all related costs incurred by the bank [4][7]. - The guarantee is a joint liability guarantee, meaning all guarantors are equally responsible for the debt [5][6]. Group 3: Financial and Related Party Information - Hubei Tian Sheng is a wholly-owned subsidiary and is not listed as a dishonest executor [3]. - Liu Shuang, the chairman and general manager, holds 7,500 shares, representing 0.0024% of the total share capital, and is also not a dishonest executor [3]. Group 4: Guarantee Contract Details - The guarantee period extends for three years after the debt fulfillment deadline, with specific conditions for extension in case of debt restructuring [8][9]. - The contract becomes effective upon signing by the involved parties [10]. Group 5: Related Transactions and Guarantees - From January 1, 2026, to the disclosure date, Liu Shuang has not engaged in any other related transactions apart from providing the guarantee [11]. - The total external guarantee amount by the company and its subsidiaries is 225 million RMB, with a balance of 128.67 million RMB, representing 6.42% of the audited net assets as of December 31, 2024 [12].

证券代码：002872 证券简称：ST 天圣 公告编号：2026-002 天圣制药集团股份有限公司 关于公司为子公司提供担保并接受关联方提供担保 暨关联交易的进展公告 公司于近日收到公司、刘爽先生共同与农商行垫江支行签署的《最高额保证 合同》，根据《最高额保证合同》，公司及刘爽先生同意为湖北天圣与农商行垫 江支行签订的主合同项下的债务提供连带责任保证担保，担保最高债权本金额为 人民币 2,700 万元。本次担保金额在公司前述审议通过的担保额度内，无需再次 提交公司董事会或股东会审议。 三、被担保人基本情况 1、基本情况 1 | 公司名称 | 湖北天圣药业有限公司 | | --- | --- | | 统一社会信用代码 | 914203046917593145 | | 成立日期 | 2009年07月15日 | | 法定代表人 卫明 | | | 注册资本 | 10,100万元人民币 | | 企业类型 | 有限责任公司（非自然人投资或控股的法人独资） | | 住所 | 湖北省十堰市郧县经济开发区天圣路1号 | | | 许可项目:药品生产;药品委托生产;发电业务、输电业务、供（配）电 | | | 业务。（依法须经批准的 ...

公司于 2026 年 1 月 19 日召开了职工代表大会，经与会职工代表表决，选 举张娅女士（简历详见附件）为公司第六届董事会职工代表董事，任期自本次 职工代表大会选举通过之日起至第六届董事会任期届满之日止。张娅女士原为 公司第六届董事会非职工代表董事，本次选举完成后变更为公司第六届董事会 职工代表董事，公司第六届董事会成员及专门委员会成员构成不变。 张娅女士符合《公司法》等法律法规及《公司章程》规定的有关董事任职 资格和条件。张娅女士当选公司职工代表董事后，公司第六届董事会中兼任公 司高级管理人员以及由职工代表担任的董事人数未超过公司董事总数的二分之 一，符合相关法律法规的要求。 特此公告。 天圣制药集团股份有限公司董事会 2026 年 1 月 20 日 证券代码：002872 证券简称：ST 天圣 公告编号：2026-003 天圣制药集团股份有限公司 关于选举职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 天圣制药集团股份有限公司（以下简称"公司"）于 2025 年 9 月 12 日召 开 2025 年第三次临时股东大会，审议通过了《关 ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.77% on January 20, with Kangzhi Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Hanshang Group (Code: 600774) with a closing price of 11.64, up 10.02% and a trading volume of 438,600 shares, totaling 489 million yuan [1] - Tainkang (Code: 301263) with a closing price of 32.71, up 7.04% and a trading volume of 138,300 shares, totaling 437 million yuan [1] - Sitaili (Code: 603520) with a closing price of 10.58, up 2.52% and a trading volume of 210,900 shares, totaling 225 million yuan [1] - Conversely, significant decliners included: - Kangyi Pharmaceutical (Code: 300086) with a closing price of 10.44, down 5.86% and a trading volume of 447,100 shares [2] - Dizhe Pharmaceutical (Code: 688192) with a closing price of 62.72, down 5.10% and a trading volume of 42,700 shares [2] - Guangji Pharmaceutical (Code: 000952) with a closing price of 7.52, down 4.93% and a trading volume of 292,200 shares [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 1.348 billion yuan from institutional investors, while retail investors contributed a net inflow of 1.109 billion yuan [2] - The capital flow for specific stocks indicated: - Huabang Health (Code: 002004) had a net inflow of 88.38 million yuan from institutional investors, but a net outflow of 73.07 million yuan from retail investors [3] - Fuxiang Pharmaceutical (Code: 300497) recorded a net inflow of 57.88 million yuan from institutional investors, with a net outflow of 102 million yuan from retail investors [3] - Xinqiao Pharmaceutical (Code: 000756) had a net inflow of 25.08 million yuan from institutional investors, but also saw a net outflow of 15.54 million yuan from retail investors [3]

Core Viewpoint - The company Tian Sheng Pharmaceutical has been found guilty of financial misconduct, including inflating profits and failing to disclose related party transactions, leading to a formal administrative penalty from regulators [1][2]. Group 1: Regulatory Actions - The Shanghai Huzi Law Firm, represented by lawyer Liu Peng, has submitted a case to the court for litigation against the company [1]. - On November 8, 2025, Tian Sheng Pharmaceutical announced it received an administrative penalty decision from regulators [1][2]. Group 2: Violations Identified - The company inflated profits by approximately 120 million yuan over the years 2017 and 2018 [3]. - Methods of misconduct included using Taihong Company to extract project funds and inflating procurement costs through a wholly-owned subsidiary to create off-the-books funds [2][3]. - The company failed to disclose its investments in and control over Taihong Company and other related parties controlled by the actual controller Liu Qun, resulting in significant omissions in its annual reports for 2017 and 2018 [2][3]. Group 3: Investor Compensation - Investors who purchased shares between April 23, 2018, and January 8, 2025, and sold or still hold shares after January 9, 2025, may join the compensation efforts [3]. - Investors are advised to prepare relevant transaction documents, such as trading records and account statements, for the legal team to assess eligibility for compensation [3].

天圣制药集团股份有限公司 证券代码：002872 证券简称：ST 天圣 公告编号：2026-001 关于公司股票交易被实行其他风险警示 相关事项的进展公告 一、实施其他风险警示的主要原因 1、控股股东刘群涉嫌侵占公司资金，由于刘群部分涉案财物已扣押、冻结、 查封，预计无法在一个月内将占用公司的资金归还。根据《深圳证券交易所股 票上市规则》相关规定，公司股票交易自 2019 年 6 月 5 日起被实施其他风险警 示。具体内容详见公司在指定信息披露媒体上刊登的《关于公司股票交易被实 行其他风险警示的公告》《关于公司股票交易被实行其他风险警示相关事项的 进展公告》。 2、公司分别于 2025 年 9 月 12 日、2025 年 11 月 7 日收到了重庆证监局出 具的《行政处罚事先告知书》（处罚字（2025）4 号）、《行政处罚决定书》 1 （（2025）4 号）。根据《深圳证券交易所股票上市规则》第 9.8.1 条第（八） 项的规定："根据中国证监会行政处罚事先告知书载明的事实，公司披露的年 度报告财务指标存在虚假记载，但未触及本规则第 9.5.2 条第一款规定情形，前 述财务指标包括营业收入、利润总额、净利润、 ...

Group 1 - The core point of the article is that Derun Electronics has been found guilty of financial fraud, with over 500 million yuan in fictitious receivables over a period of two and a half years, leading to multiple financial reports containing false records [2][4] - Derun Electronics will be subject to risk warnings starting January 6, with its stock name changed to ST Derun, and related parties have been fined over 20 million yuan [2][3] - In 2025, more than 80 A-share companies and over 200 related individuals were investigated for violations, with around 40% being ST companies, indicating a trend of stricter regulatory oversight in the capital market [2][3] Group 2 - The article highlights that several A-share companies have been investigated for financial fraud, with significant penalties imposed, including ST Dongtong and ST Tiansheng, which were found to have inflated revenues and profits over multiple years [4][5] - A total of 29 A-share companies were delisted in 2025, with some facing mandatory delisting due to serious violations, such as ST Suwu, which was found to have inflated revenues by 1.772 billion yuan and profits by 75.9975 million yuan [6][7] - The regulatory environment is described as having a "zero tolerance" approach, with ongoing efforts to enhance market supervision and improve the delisting system to maintain a balanced and healthy capital market [8][9] Group 3 - The article discusses the need for improved governance and the use of technology to more accurately target illegal activities, emphasizing the importance of intermediary institutions in preventing misconduct during the listing process [10][11] - It is suggested that a reputation mechanism for intermediary institutions should be established to increase the costs associated with collusion with listed companies [11]